GleamWall
中文EN

NKTX Nkarta, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$90.43M$96.74M
SG&A expense$31.57M$31.45M
Operating income-$122.00M-$128.19M
Income tax$0$0
Net income-$104.08M-$108.79M
EBITDA-$112.80M-$118.99M
EPS (basic)-1.41-1.60
EPS (diluted)-1.41-1.60
Dividends declared per share0.000.00
Weighted avg. shares (diluted)73.99M67.87M
Balance sheet
Cash & equivalents$39.63M$27.87M
Short-term investments$236.65M$239.48M
Current assets$282.51M$273.34M
PP&E, net$66.72M$74.66M
Total assets$404.21M$501.20M
Current liabilities$22.27M$18.92M
Total liabilities$91.88M$93.23M
Shareholders' equity$312.32M$407.98M
Shares outstanding71.08M70.65M
Cash flow statement
Operating cash flow-$88.70M-$99.70M
Capital expenditure$1.21M$4.41M
Free cash flow-$89.91M-$104.11M
Investing cash flow$100.32M-$129.56M
Financing cash flow$141,000$226.08M
Depreciation & amortization$9.20M$9.20M
Stock-based compensation$8.56M$16.73M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.